Funds dry up for mRNA vaccines amid US political storm
The amount of equity flowing into companies developing mRNA-based vaccines has significantly declined so far in 2025, suggesting the financial…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
Trogenix lands $95m Series A, backed by Eli Lilly, for brain cancer therapy
Trogenix has raised £70m ($95m) in Series A financing to help bring its “Trojan horse” cancer treatment into clinical trials,…
-
Rocket ditches blood disorder gene therapy in ongoing pipeline pivot
The flight path towards a first approved product for Rocket Pharmaceuticals has been hit with turbulence, after the biotech culled…
-
FDA approves mifepristone generic as political abortion war rages on
The US Food and Drug Administration (FDA) has approved Evita Solutions’ generic form of mifepristone, one of the two medications…
-
Halozyme eyes microparticles in $900m Elektrofi acquisition
Halozyme Therapeutics has agreed to acquire US-based Elektrofi in a deal worth up to $900m, which will see it add…
-
AstraZeneca launches DTC platform amid US pricing pressures
AstraZeneca has launched an online direct-to-consumer (DTC) medicine platform in the US, joining a growing list of companies opting for…
-
Drugmakers point to US expansion plans amid Trump’s 100% drug tariff
The US will impose a 100% tariff on certain pharma products entering the country, the latest move by the Trump…
-
MSD pays up to nearly $600m for Evaxion’s mystery vaccine candidate
Merck & Co (MSD) has taken the first of two possible plunges in its ongoing collaboration with Evaxion, gaining the…
-
Basilea in line for $159m of US federal funding for UTI antibiotic pill
The Biomedical Advanced Research and Development Authority (BARDA) in the US will support Basilea’s development of a new type of…
-
Podcast: How oral GLP-1RAs are set to impact the obesity market
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have taken the weight-loss world by storm. Even beyond the healthcare world, Ozempic, Wegovy and…